Shilpa Medicare Limited Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
530549 Community Narratives
530549: Global Expansion Will Accelerate With Upcoming Product Launches
Oncology Portfolios And Biosimilars Will Fuel Global Healthcare Expansion
US And EU Regulatory Pressures Will Undermine Legacy Pipelines
Oncology Portfolios And Biosimilars Will Fuel Global Healthcare Expansion
View narrative530549: Global Expansion Will Accelerate With Upcoming Product Launches
View narrativeUS And EU Regulatory Pressures Will Undermine Legacy Pipelines
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
530549: Higher Margins And Recall Management Will Support Stronger Future Outlook
530549: Dividend Plans And Office Shift Will Shape A Balanced Outlook
530549: Upcoming Dividend And Office Shift Will Signal Limited Upside Potential
Snowflake Analysis
Shilpa Medicare Limited Key Details
- 15.20
- 69.35%
- 17.66%
- 25.5%
About 530549
- Founded
- 1987
- Employees
- 1241
- CEO
- Website
View website
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.